We would love to hear your thoughts about our site and services, please take our survey here.
And another 100,000 bought by Paul Hodges, a Non-Executive Director of the Company, had purchased 100,000 Ordinary Shares of 1 pence each ("Ordinary Shares") in the Company at a price of 31 pence each.
Following this transaction, Mr Hodges is interested in 1,381,818 Ordinary Shares in the Company, representing 2.0 per cent of the issued share capital of the Company.
100,000 bought at 30p yesterday near the close.
Interested to see if the 100,000 buy order is still there today, as someone has had an order for 100,000 shares at 26p sitting there for a few days now, or was it the director, and he’s been forced to pay 30p instead of 26p, we’ll see later.
It may have taken a week to sink in but 30p paid today, certainly going in the right direction now.
Hopefully WPHO can hold the gains.
Seems encouraging,
“Entering 2023, the production capacity of the Group was fully booked by customer orders for deliveries in the first half of 2023. Currently, the Group is focused on increasing capacity by at least 100% to be implemented mid-year 2023 and planning for a further doubling of capacity when entering year 2024”
So the DD sale was actually a buy, that’s more like it.
Yes agreed, 300+ test to date, not monthly.
What is obvious is the build up in repeat orders, which must be happening having 300 tests from 20+ oncologists.
The test was initially launched in the US in February 2022. During the period, in November 2022, we hit the key milestone of 100 CiRT tests ordered, around nine months after launch. The next 100 tests were ordered in about half that time and we recently processed the 300th order less than three months later, in mid-May 2023. The period ended with a total of 24 US oncologists 'on the books', 20 of whom had placed orders for CiRT tests since the beginning of 2023 and we have continued to grow our physician base post-period end.
"the average amount paid for reimbursed tests to date is between $2,000 and $2,500, against a list price of $5,500".
Hi bottom_feeder.
“So all in all it looks like OBD is going to shut up shop”
That’s seems a massive assumption going on todays RNS.
We could instead highlight the beginning of Dr Jon Burrows statement…
“The first half of our financial year saw excellent progress across the business.
There was sustained growth in orders of Episwitch Cirt tests, which has continued post-period end. Overwhelming demand for the PSE blood test after the announcement of its high accuracy performance led the group to accelerate its development”.
Hardly comments of a company ready to “shut up shop”.
Yes OBD have spent a lot of the funds raised, but as stated the US subsidiary has leased and moved into 7800 sq ft of laboratory space, these extra costs should not be repeated.
UK clinical lab is also under development, costs of which will not be repeated.
New sales and operation roles in the US and new roles in the UK, which should generate income.
£900,000 in UK tax credits received in April to add to the cash balance.
300,000 EpiSwitch tests processed in May, (which still has 1 day to go).
As the BOD states, the going concern statement was said in the annual reports in 2021 & 2022, and repeat today.
Seems like cash will be needed, “shutting up shop” far from the truth from my reading.
It’s the going concern statement that worries people, but the Bod are required to point out the obvious.
ST recommended these in today’s Alpha article, reads well, I personally wasn’t aware of them before, happy to see you’re invested here Guitarsolo.
I’ve picked up some mainly for the dividend income.
Further, the Company announces that the Broker Option announced on 11 May 2023 has now closed. No shares will be issued under the Broker Option.
Kc911, it’s painful isn’t it :-)
Suspension, not the best outcome, but in real terms is only 8 working days, after taking into account two bank holidays and weekends.
I have sold half at 115.9238p this morning though.
Just topped up too at 93.83p in two deals.
Thought I was onto a winner initially buying at 99p, riding the rise above 130p+ and receiving the 6.3p dividend, but I agree Sisyphus, fund inflows will build going forward.
Half year results in May I think, so not too long for an update.
Very late RNS today, hopefully just a short suspension for AMOI, until the results are audited and released by our new auditors RPG Crouch Chapman LLP.
While not the largest order extension it certainly is appreciated and good to know WPHO are going in the right direction.
Just need the share price to be a little more positive.
I’ve added today with some of this year’s ISA allowance, hopefully this will be the year we get back above the £1 mark for starters.
With ii, divi paid in $ in a SIPP, and in £ in an ISA, as they only allow GBP in an ISA.
Just do an FX conversion in the SIPP, after transaction cost, occasionally I end up with a slightly higher divi.
Don’t usually take up the offer myself, unless I know the price, but have had a go.
My average is 77.3p, held since 2/2/19, so I’ll be happy if I can keep the average at 80p or less, but being eligible for the next dividend swung it for me.
The semi-annual dividends arising on the preference shares in June and December 2022 were paid on their respective due dates. In addition, a payment of 10p per share of arrears of dividend on the group’s preference shares was paid at the end of 2022. Provided that operational performance and cash flows continue at satisfactory levels, the directors continue to plan for the elimination of all arrears of dividend on the preference shares by the end of 2023.
So if all goes well 16p to be paid in total over the next 11 months, 2 x 4.5p & 7p of arrears.